Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C09DB01

Dafiro(amlodipine;valsartan)

Hypertension

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 15/01/2007

INN: amlodipine;valsartan

Indication

Treatment of essential hypertension. Dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Dafiro — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.